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Abstract
This investigation aimed both to delineate the current status of community-acquired acute bacterial meningitis and to produce data on
the interrelationships between clinical, laboratory and therapeutic parameters in the elderly. This retrospective cohort study was con-
ducted in 28 Turkish institutions in 159 culture-positive patients over the age of 50 years. Streptococcus pneumoniae was the most com-
mon pathogen (69.2%), followed by Listeria monocytogenes (8.8%). For this reason, antilisterial antibiotics such as ampicillin or
benzylpenicillin should be added to the therapeutic regimen. Pathogen-speciﬁc mortality did not vary between S. pneumoniae and L. mon-
ocytogenes. The overall mortality was 2.5% at the third day, 12.6% at the seventh day, 20.1% at the 14th day and 21.4% at the 21st day.
The risk factors for fatality were increasing age, the presence of stupor, sepsis and inappropriate antibiotic administration. Cerebrospinal
ﬂuid (CSF) leukocyte counts and CSF/blood glucose ratios were lower in patients who died. Fever did not differ between survivors and
fatal cases. The mean duration of antibiotic therapy in survivors was 16.3 ± 6.4 days. One-ﬁfth of the patients had complications, and in
5.7% of the patients sequelae persisted at follow-up.
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Introduction
In the literature, few studies of bacterial meningitis have
focused on the characteristics of the illness in the elderly, and
these publications are relatively old [1–4]. One current investi-
gation did evaluate the epidemiology of bacterial meningitis in
the elderly in The Netherlands, but the demographic and
microbiological characteristics of Turkey, located at the south-
east border of Europe, appear to be very different [5,6]. The
rate of antibiotic resistance in pneumococci and in commu-
nity-acquired Gram-negative pathogens, in particular, is quite
high in Turkey, and this could obviously affect therapeutic out-
comes [7,8]. Bacterial meningitis in elderly patients is associ-
ated with greater diagnostic difﬁculty as well as with higher
mortality [9]. This study aimed both to delineate the current
status of community-acquired acute bacterial meningitis (CA-
ABM) among the elderly in Turkey and to produce data on the
interrelationships among clinical, laboratory and therapeutic
parameters in this group of patients.
Materials and Methods
This retrospective cohort study was conducted in 28 Turkish
medical institutions. Overall, 159 patients (69 females and 90
males), hospitalized after the year 2000, were included in the
study. The mean age of the cases was 63 years (SD = 9.0,
min: 50, max: 80). Medical records of all patients with
CA-ABM were retrieved from a computer database gener-
ated for statistical evaluation. In Turkey, the life-expectancy
is 71 years for males and 75 years for females [10]. As
50 years of age is a critical threshold for a shift in the causa-
tive agents of CA-ABM [11], we enrolled patients over the
age of 50 years.
Patients with hospital-acquired meningitis, deﬁned as men-
ingitis that occurred during hospitalization or within 1 week
after discharge, were excluded. Patients with neurosurgical
devices were also excluded from the study. [12]. All patients
suspected to be suffering from CA-ABM after initial clinical
evaluation were subjected to lumbar puncture. The presence
of leukocytes and protein and glucose levels in the cerebro-
spinal ﬂuid (CSF) and blood biochemical markers were evalu-
ated. Positive CSF culture was the primary criterion for
inclusion of a patient in the study. In addition, patients whose
CSF cultures yielded no growth, but in whom there was evi-
dence of inﬂammatory response in the CSF and whose blood
cultures yielded a pathogen consistent with meningitis, were
also included in the study. CSF opening pressure was
recorded as an observation, but numerical values were gen-
erally not recorded. For this reason, these data were
excluded from the study.
As no Turkish consensus guidelines exist for the manage-
ment of CA-ABM, Turkish clinicians generally utilize foreign
guidelines [11]. Inappropriate antibiotic therapy was deﬁned
as the use of an antimicrobial agent that subsequent antibi-
otic susceptibility testing showed to be ineffective. CLSI
guidelines are used to detect antibiotic resistance in Turkey.
Clinical sepsis was recorded according to the deﬁnitions of
a consensus committee of US experts in 1992 [13]. Coma
was deﬁned as unarousable unresponsiveness. The terms
‘confusion’ and ‘stupor’, which are described more exten-
sively elsewhere, referred to states between alertness and
coma [14]. Glasgow coma scales of the patients could not be
provided. Steroids were used in all cases with mental status
changes (dexamethasone or prednisolone; for 2–11 days,
median 4 days).
The statistical analyses were performed with the
SPSS 12.0 (SPSS Inc., Chicago, IL, USA) program. Results
were given as mean ± standard deviation, median (minimum–
maximum) for continuous variables and frequencies, and per-
centages for categorical variables. The comparisons between
the two groups were analysed with independent-samples
t-tests or Mann–Whitney U-tests, as appropriate. The com-
parisons in more than two groups were performed with
one-weay ANOVA or Kruskal–Wallis variance analysis, as
appropriate. Spearman or Pearson correlation analyses were
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used to determine the linear association. Chi-square tests or
Fisher’s exact tests were used for the comparisons of
categorical variables. Survival analysis was performed with
log-rank tests and Cox proportional regression analysis. All
of the variables that appeared to be related to mortality
were included in univariate analysis. Although some of the
variables did not have a signiﬁcant p-value, we included
clinically important variables in a multivariate analysis. A
p-value of <0.05 was accepted as statistically signiﬁcant.
For statistical comparisons, the bacterial isolates were
grouped as follows: Streptococcus pneumoniae, Listeria mono-
cytogenes, enteric Gram-negative bacteria, coagulase-negative
staphylococci, other Streptococcus species, Neisseria meningiti-
dis and Staphylococcus aureus.
Results
Laboratory data
Laboratory data on the patients are shown in Table 1. CSF
culture positivity was 92.5%. The rate of positive blood cul-
ture in the case of negative CSF culture was 7.5%. In 23.9%
of the cases, the same pathogen was detected in both CSF
and blood cultures. In nine patients (5.7%), the CSF white
blood cell (WBC) count was found to be lower than 100/
mm3. In one case, CSF pleocytosis was not detected, but
S. pneumoniae was isolated from the CSF culture, and the
patient died on the day of hospital admission.
CSF glucose levels were signiﬁcantly higher among diabetic
patients than among non-diabetic patients (p = 0.008).
Accordingly, CSF/blood glucose ratios were signiﬁcantly
lower in diabetic patients than in non-diabetic patients
(p = 0.032). CSF WBC counts and CSF/blood glucose ratios
were signiﬁcantly lower for fatal cases than for survivors
(p = 0.005 and p = 0.013, respectively). The CSF WBC
counts of the patients with immunosuppressive disorders
were signiﬁcantly lower than those of immunocompetent
patients (1561.6, standard deviation (SD) 1905.8; 4529.6,
SD 6963.6; p 0.008). Similarly, CSF/blood glucose ratios in the
immunosuppressed group were signiﬁcantly lower than those
in the immunocompetent group (0.249, SD 0.171; 0.165,
SD 0.156; p = 0.004). When the CSF/blood glucose ratios
were compared between the patients with immunosup-
pressive disorders other than diabetes and those without
immunosuppressive disorders, there was no signiﬁcant differ-
ence (p = 0.151). The blood WBC count, erythrocyte sedi-
mentation rate and C-reactive protein level were similar in
the immunocompetent and immunosuppressed groups. There
was no statistical association among the biochemical markers
CSF WBC, blood WBC, erythrocyte sedimentation rate,
C-reactive protein, CSF/blood glucose ratios, CSF protein
levels and increase in age (p-values of 0.296, 0.114, 0.260,
0.791, 0.450 and 0.182, respectively).
Clinical data
Demographic data on the patients are shown in Table 1, and
clinical ﬁndings are presented in Table 2. There were 64
coexisting immunosuppressive disorders, which are shown in
Table 3, in 46 patients. Altered mental status was seen in
81.8% of the patients. In all patients, there was at least one
of the three clinical features of headache, fever and altered
mental status; in 70% of the patients, at least two of these
three features were detected; and this classic triad of ﬁnd-
ings was complete in 39% of the patients. Although 88% of
the patients complained of fever, signiﬁcant fever levels
(more than 38C) were not detected in 30% of the patients
on admission. The mean body temperature was 38.3C
(SD 1.0C, minimum 36C, maximum 40C). There was no
signiﬁcant association between body temperature and
increasing age (p 0.826).
In our cohort, the initial empirical antibiotic choices were
as follows. The majority of patients, 135 (85%), were treated
with ceftriaxone-based or cefotaxime-based regimens. Eight
patients (5%) were treated with meropenem, ten (6.3%)
TABLE 1. Demographic and laboratory data of the 159
patients
n %
Causative agents
Streptococcus pneumoniae 110 69.2
Listeria monocytogenes 14 8.8
Staphylococcus epidermidis 7 4.4
Other streptococci 5 3.1
Staphylococcus aureus 4 2.5
Escherichia coli 4 2.5
Neisseria meningitidis 4 2.5
Enterococci 3 1.9
Haemophilus inﬂuenzae 2 1.3
Othera 6 3.8
CSF appearance
Turbid 138 86.4
Clear 10 6.4
Purulent 9 5.7
Haemorrhagic 2 1.4
Laboratory parameters Median Minimum–maximum
CSF
WBC count (cells/mm3) 1445 0–44 000
Glucose (mg/dL) 21 0–285
Protein (mg/dL) 300 2–3670
Blood 1000–57 800
WBC count (cells/mm3) 16 950 63–558
Glucose (mg/dL) 138.5 1–453
CRP (mg/L) 48 2–140
ESR (mm/h) 60
CSF/blood glucose level 0.191 0.0–0.604
CRP, C-reactive protein; CSF, cerebrospinal ﬂuid; ESR, erythrocyte sedimenta-
tion rate; SD, standard deviation; WBC, white blood cell.
aOther: Alcaligenes faecalis, Corynebacterium genitalium, Enterobacter cloacae, Klebsi-
ella pneumoniae and Proteus vulgaris as single cases. In one patient, dual aetiology
was detected with Staphylococcus epidermidis and P. vulgaris.
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were treated with crystallized penicillin, and six (3.8%) were
treated with ampicillin. The mean duration of antibiotic treat-
ment of survivors was 16.3 ± 6.4 days (median 14 days, mini-
mum 8 days, maximum 42 days). In 87.4% of the cases,
empirical therapy that was subsequently conﬁrmed to be suit-
able by antibiotic susceptibility tests was employed.
Inappropriate initial antibiotic therapy, which was afterwards
modiﬁed because of antibiotic resistance in the infecting
microorganism, resulted in a 46.2% overall survival rate,
whereas appropriate initial therapy led to 80.6% survival. The
resistance patterns of S. pneumoniae and L. monocytogenes, the
two major causative agents, are presented in Table 4, and a
comparison of S. pneumonaie and L. monocytogenes meningitis
is shown in Table 5. There was no association between the
causative agents and neurological complications or fatality
(p 0.756 and p 0.725, respectively).
There were 125 patients (78.6%) who recovered from the
disease, and 34 patients (21.4%) died despite antibiotic treat-
ment. The mean age of the patients who died was 67.0 years
(SD 9.1 years), and the mean age of the patients who recov-
ered was 61.9 years (SD 8.6 years). Sixteen of 50 patients
(32%) with clinical sepsis died, and 18 of 109 (16.5%) patients
whose condition on admission did not meet the criteria for
sepsis died. The cause of death was reported in the medical
records for only seven of the 34 patients. Six patients died
because of multiple organ dysfunction following septic shock,
and one because of intercurrent hospital-acquired pneumo-
nia. The overall fatality rate was 2.5% at the third day, 12.6%
at the seventh day, 20.1% at the 14th day, and 21.4% at the
21st day. The Kaplan–Meir survival curve of the patients is
shown in Fig. 1. The effects of different variables on fatality
in univariate and multivariate analyses are shown in Table 6.
Discussion
The two most important epidemiological changes in CA-
ABM have been the reduction in the incidence of Haemophi-
lus inﬂuenzae meningitis and the emergence of antibiotic-
resistant pneumoccocci [15]. Today, pneumococci are known
as the major pathogens in CA-ABM [16,17], and this was
also the case in our elderly patients. Fortunately, the inci-
dence of the formerly more prevalent H. inﬂuenzae was
as low as 1.3%, and the agent of epidemic meningitis,
N. meningitidis, was detected in 2.5% of the patients in our
study. Pneumococci were responsible for more than two-
thirds of all cases, and one-ﬁfth of the patients infected with
TABLE 2. Clinical ﬁndings
Complaints Number of patients %
Fever 139 87.6
Headache 87 54.7
Vomiting 72 45.3
Nausea 61 38.4
Ear pain 22 13.8
Dizziness 7 4.4
Rhinorrhoea 7 4.4
Incontinence 4 2.5
Diplopia 3 1.9
Visual loss 1 0.6
Physical ﬁndings
Nuchal rigidity 126 79.2
Confusion 102 64.2
Disorientation 22 13.8
Stupor 16 10.1
Agitation 12 7.5
Labial herpes 9 5.7
Rales 14 9.0
Convulsions 4 2.5
Coma 3 1.9
Hepatomegaly 3 1.9
Oral candidiasis 2 1.2
Coexisting infections
Respiratory infections
Otitis and sinusitis 20 12.6
Community-acquired pneumonia 14 8.8
Presence of sepsis 50 31
Complications 31 19.5
Infectious
Subdural empyema 1 0.6
Septic arthritis 1 0.6
Extraventricular shunt infection 1 0.6
Hospital-acquired pneumonia 2 1.3
Aspiration 1 0.6
Peripheral venous catheter infection 1 0.6
Non-infectious
Hydrocephalus 6 3.8
Hearing loss 5 3.1
Acute renal failure 4 2.5
Convulsions 3 1.9
Hemiparesis 2 1.3
Hemiplegia 1 0.6
Subarachnoid haemorrhage 1 0.6
Polyneuropathy 1 0.6
Depression 1 0.6
Dysarthria 1 0.6
Acute lung oedema 1 0.6
Atelectasis 1 0.6
Sequela 9 5.7
Hearing loss 5 3.1
Hemiparesis 1 0.6
Hemiplegia 1 0.6
Polyneuropathy 1 0.6
Depression 1 0.6
Dysarthria 1 0.6
TABLE 3. Coexisting immunosuppressive conditions
Overall
(n = 159)
Listeria cases
(n = 14)
Type 1 diabetes mellitus 20 (12.6%) 1
Type 2 Diabetes mellitus 5%
Malignancy 5% 1
Steroid use 3.8% 1
Multiple myeloma 3.1% 1
Chronic renal insufﬁciency 2.5%
Chemotherapy 1.9% 1
Splenectomy 1.9% 1
Pemphigus 1.3%
Oral candidiasis 0.6%
Neutropenia 0.6%
Still’s disease 0.6%
Anti-TNF use 0.6%
Alcoholism 0.6% 1
Total 64 disorders in
46 patients
7 disorders in
7 patients
TNF, tumour necrosis factor.
1226 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1223–1229
pneumococci died. Antibiotic resistance in invasive pneumo-
cocci has been increasing steadily in Turkey [8,18,19]. In our
study, penicillin resistance was found in 13% of pneumococci.
Thus, penicillin is not a reliable empirical treatment option in
pneumococcal meningitis (PM). Resistance to ceftriaxone was
reported in 1% of pneumococci. Ceftriaxone or cefotaxime
seem to be effective in the management of PM, and the 23-
valent pneumococcal vaccine appears to be effective in pre-
venting pneumococcal disease in Turkey [20].
L. monocytogenes is an infectious agent in newborns,
pregnant women, immunosuppressed people and the
elderly [21–23]. Our investigation shows that it is a signiﬁ-
cant pathogen for this age group in Turkey, and immuno-
suppresive conditions were present in half of the patients.
In our study, all L. monocytogenes strains were susceptible
to benzylpenicillin or ampicillin, but all were resistant to
cephalosporins. Given the fact that benzylpenicillin and
ampicillin are not suitable choices in PM (which accounts
for the majority of cases) in Turkey, combined therapy
would be the rational approach [24]. In our study, the fea-
tures of L. monocytogenes meningitis were very similar to
those of PM. The CSF/blood glucose ratio was higher in
listerial meningitis than in PM, whereas the CSF WBC
count was higher in the latter.
The classic triad of acute bacterial meningitis consists of
fever, headache, and changes in mental status. All of our
patients exhibited at least one of these. Approximately two-
thirds of the patients presented two of the classic triad,
whereas only 39% had all three. Similarly, most adult patients
with CA-ABM are known to have high fevers, often greater
than 38C [25]. However, in this older population, 30% of the
patients did not. Hypothermia, which is deﬁned as a core tem-
perature below 35C [26], was not detected in any of the
patients. Mental status was altered in three-quarters of the
patients, most of whom were confused. We could not evaluate
the effect of coma, as there were only three comatose cases,
but the presence of stupor was a poor prognostic factor.
TABLE 4. Antibiotic resistance proﬁles (no. (%)) of Streptococcus pneumoniae and Listeria monocytogenes
PEN AMP CXN E CLN CLA RIF LEV SXT
S. pneumoniae 14/110 (13) 1/110 (1%) 5/55 (9) 0/38 (0) 2/34 (6) 2/101 (2) 0/29 (0) 9/39 (23)
L. monocytogenes 0/14 (0) 0/14 (0) 14/14 (100)
PEN, penicilllin; AMP, ampicillin; CXN, ceftriaxone; E, erythromycin; CLN, clindamycin; CLA, chloramphenicol; RIF, rifampicin; LEV, levoﬂoxacin; SXT, trimethoprim–sulpha-
methoxazole.
TABLE 5. Comparison of Strepto-
coccus pneumonaie and Listeria
monocytogenes meningitis
S. pneumonaie L. monocytogenes p-value
Coma (%) 2.7 0.0 1.00
Stupor (%) 10.9 14.3 0.66
Confusion (%) 65.5 57.1 0.56
Neck stiffness (%) 77.3 78.6 1.00
Immunosuppression (%) 26.4 42.9 0.22
Fatality (%) 22.7 28.6 0.74
Neurological complication (%) 8.2 0 0.60
Age, years 61 (50–86) 61 (50–80) 0.92
Fever (C) 38.5 (36–40) 38.5 (36.8–39.8) 0.90
CSF WBC count (/mm3) 1600 (10–44 000) 660 (20–1983) 0.03
CSF/blood glucose 0.12 (0.0–0.60) 0.23 (0.06–0.46) 0.019
CSF protein (mg/dL) 317 (2–3670) 168.5 (47–1400) 0.06
Blood WBC count (/mm3) 16 500 (1000–45 500) 22 000 (8300–31 300) 0.60
ESR 60 (11–140) 57 (30–88) 0.99
CRP 48 (1–453) 64 (14–248) 0.34
CRP, C-reactive protein; CSF, cerebrospinal ﬂuid; ESR, erythrocyte sedimentation rate; WBC, white blood cell.
Unless otherwise stated, the results are given as median (minimum–maximum).
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FIG. 1.Overall survival of the patients over time.
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Fatality rates of CA-ABM are believed to be related to
the various infecting microorganisms [27], but in our elderly
patients we could not establish signiﬁcant correlations
between fatality or the presence of complications and the
causative agents. Reasons for this difference may be the
lower numbers infected by pathogens other than pneumo-
cocci, or the confounding factors related to altered immunity
in this age group. Moreover, we could not establish a corre-
lation between the delay from onset of symptoms to antibi-
otic administration and fatality: there was no signiﬁcant
difference between patients given antibiotics within 2 days
following the onset of symptoms and those treated later.
This ﬁnding may have resulted from the initial symptoms in
these patients being unrelated to meningitis itself, but rather
to coexisting infections. However, the rational approach
would be to administer antimicrobial therapy as soon as pos-
sible after the diagnosis of bacterial meningitis is suspected
or proven [11]. On the other hand, inappropriate antibiotic
use was signiﬁcantly associated with higher fatality rates,
even though the treatment was later modiﬁed in response to
the results of antibiotic susceptibility tests. As CA-ABM is a
fatal infection, rational antibiotic use is very important, par-
ticularly in the presence of sepsis, which was found to be a
poor prognostic factor for mortality in our study. Thus, sur-
veillance of meningeal pathogens in a given community is
essential for optimizing empirical therapies.
Pneumococcal infections are associated with immunosup-
pressive conditions. In addition, it is known that immuno-
suppressive conditions mediate worse outcomes in systemic
infections [28–35]. In our patients with immunosuppressive
disorders, CSF/blood glucose ratios were signiﬁcantly lower
than in the immunocompetent patients. When the diabetic
patients were excluded, however, there was no signiﬁcant
difference between the CSF/blood glucose ratios in the two
groups. In contrast, although CSF glucose levels were
higher, the CSF/blood glucose ratios were lower in diabetic
patients. This is probably due to the rapid utilization of
excessive CSF glucose by the infecting agent in the course
of CA-ABM in diabetic patients. Lower CSF/blood glucose
ratios in fatal cases may be indicative of higher bacterial
loads. Furthermore, lower CSF WBC counts were detected
in patients in our study who died. In the subset of immu-
nocompromised elderly people, however, this was not a
poor prognostic factor. The clinical disease observed when
bacteria enter the CSF is a result of complex interactions
between the components of bacteria and the host inﬂam-
matory response. These interactions inﬂuence both the
blood–brain barrier and neuronal integrity. In this context,
the immunosuppression may not have marked negative
effects on outcome in CA-ABM.
The ageing process is characterized by structural and func-
tional changes affecting all organ systems [36]. Although sig-
niﬁcant associations could not be established among fever
levels, numerical values of biochemical or inﬂammatory
markers or increasing age, the fatality rate was higher in this
elderly population.
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TABLE 6. Effects of different vari-
ables on fatality, in univariate and
multivariate Cox proportional
regression analysis
Unadjusted
HR 95% CI p-value
Adjusted
HRa 95% CI p-value
Age 1.05 1.01–1.09 0.007 1.04 1.01–1.08 0.019
Timing of antimicrobials in
relation to onset of symptomsb
1.30 0.58–2.93 0.53
Immunosuppression 1.42 0.70–2.86 0.33 1.29 0.62–2.66 0.49
Sepsis 2.38 1.09–5.19 0.027 2.16 1.05–5.82 0.041
Inappropriate antimicrobial
treatment
3.90 1.68–9.08 0.002 3.70 1.57–8.70 0.003
Male sex 1.88 0.90–3.94 0.09 1.94 0.92–4.09 0.08
Neurological complication 2.64 0.36–19.39 0.34 9.54 0.58–156.83 0.11
Confusion 1.49 0.69–3.19 0.31 3.13 0.73–13.51 0.13
Stupor 2.93 1.27–6.75 0.011 7.91 1.64–38.24 0.01
CI, conﬁdence interval; HR, hazard ratio.
aAdjusted for age, gender, immunosupression, sepsis, neurological complication, confusion, stupor, and inappropriate
antimicrobial treatment.
bReference group includes patients receiving antibiotics within 48 h from onset of symptoms. These data are included
for 126 of 159 cases, and as the result of univariate analysis is not signiﬁcant, this parameter is excluded from the
multivariate analysis.
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